Market Cap (In USD)
1.35 Billion
Revenue (In USD)
886 Thousand
Net Income (In USD)
-338.79 Million
Avg. Volume
594.47 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 15.6-47.97
- PE
- -
- EPS
- -
- Beta Value
- 2.91
- ISIN
- US00773J2024
- CUSIP
- -
- CIK
- 1636282
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Cameron Turtle DPHIL, Ph.D.
- Employee Count
- -
- Website
- https://www.spyre.com
- Ipo Date
- 2016-04-07
- Details
- Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. The company's pipeline includes extended half-life antibodies targeting a4ß7, TL1A, and IL-23. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was founded in 2013 and is based in Waltham, Massachusetts.
More Stocks
-
2050Savola Group Company
2050
-
PRD
-
ALBPK
-
KOREKORE Mining Ltd.
KORE
-
DSAIFDeepSpatial Inc.
DSAIF
-
AAIL
-
2015
-
VARN